Sarepta Therapeutics — Third Quarter 2026 Earnings Summary

Sarepta Therapeutics reported third-quarter 2026 net product revenues of approximately $323.8 million, driven by $240.3 million from PMO products and $83.5 million from ELEVIDYS. The company achieved a GAAP operating loss of $9.0 million and a non-GAAP operating income of $22.9 million, while maintaining a cash position of approximately $998.7 million. Management updated its full-year 2026 guidance, raising the lower end of total net product revenue expectations to $1.25 billion and narrowing the expense range. Clinical progress includes upcoming multiple ascending dose data for SRP-1003 in DM1 and SRP-1001 in FSHD expected by year-end, with preparations for Phase 3 development underway.